Cerebral folate deficiency

Douglas J Lanska MD FAAN MS MSPH (

Dr. Lanska of the University of Wisconsin School of Medicine and Public Health, the Medical College of Wisconsin, and IM Sechenov First Moscow State Medical University has no relevant financial relationships to disclose.

)
Originally released October 16, 2012; last updated October 21, 2020; expires October 21, 2023

Overview

Cerebral folate deficiency is characterized by decreased cerebral concentrations of 5-methyltetrahydrofolate in the presence of normal blood folate concentrations within the reference range. Patients may have developmental delay or regression, hypotonia, seizures, visual disturbances, and autistic features. Therapy with oral folinic acid is effective for treating many aspects of the disorder. The disorder is caused by decreased transport of folate across the blood-brain barrier due to decreased function of folate receptor alpha. In some individuals, the disorder may be caused by autoantibodies directed against folate receptor alpha; in others, mutations in the FOLR1 gene, which encodes folate receptor alpha, have been identified.

Key points

 

• Cerebral folate deficiency may be caused by decreased ability to transport folate across the blood-brain barrier because of decreased function of folate receptor alpha or due to specific disorders of folate metabolism.

 

• Cerebral folate deficiency due to folate transport disorders can be caused by blocking autoantibodies against folate receptor alpha or mutations in the FOLR1 gene.

 

• Affected individuals with cerebral folate deficiency due to mutations in the FOLR1 gene are normal at birth, but usually in the first year of life these children exhibit deceleration of head growth and developmental delay or regression, usually in the first year of life.

Historical note and terminology

Neurologic disease was first linked to folate deficiency in 1973 (Reynolds et al 1973) and low CSF folate levels were first reported in 1981 (Botez and Bachevalier 1981). Cerebral folate deficiency was first reported by Ramaekers and colleagues in 2002 (Ramaekers et al 2002). As originally defined in 2004 by Ramaekers and Blau, cerebral folate deficiency is characterized by extremely low concentrations of 5-methyltetrahydrofolate (MTHF), the predominant circulating form of folate, in the cerebrospinal fluid in the presence of normal blood folate concentrations (Ramaekers and Blau 2004; Mastrangelo 2018).

Image: 5-methyltetrahydrofolate chemical structure
The term “cerebral folate deficiency” is also sometimes used to describe conditions where CSF MTHF is low, in the presence of low or undefined peripheral folate levels (Pope et al 2019), although this muddies the concepts and is confusing.

The term “idiopathic cerebral folate deficiency” had been suggested to differentiate it from cerebral folate deficiency that can develop in disorders such as Rett syndrome or Kearns-Sayre syndrome (Ramaekers and Blau 2004); however, because the etiology is known, the “idiopathic” descriptor seems inappropriate. More recent categorizations of disorders of folate metabolism have classified cerebral folate deficiency into primary and secondary forms (Pope et al 2019).

Primary causes of cerebral folate deficiency include various inborn errors of metabolism:

 

• Folate receptor alpha (FRα) deficiency
• Dihydrofolate reductase (DHFR) deficiency
• Methylenetetrahydrofolate reductase (MTHFR) deficiency
• Methenyltetrahydrofolate synthetase (MTHFS) deficiency

Secondary causes of cerebral folate deficiency include a diverse collection of disorders, for many of which the precise metabolic disruption remains obscure:

 

• Antibodies to folate receptor alpha
Mitochondrial disorders (especially Kearns-Sayre syndrome)
• Serine deficiency syndromes
• Dihydropteridine reductase (DHPR) deficiency
• Aromatic l-amino acid decarboxylase (AADC) deficiency
• Folinic acid-responsive seizures (allelic with pyridoxine-dependent epilepsy)

Secondary cerebral folate deficiency in adults, when defined simply as low MTHF concentrations in the CSF (in the presence of undefined peripheral folate levels), is a heterogeneous but potentially treatable condition (Masingue et al 2019). Cerebral folate deficiency in adults should be considered in patients with mitochondrial diseases, primary brain calcifications, and unexplained complex neurologic disorders, especially if associated with white matter abnormalities (Masingue et al 2019).

Disorders that produce low CSF 5-MTHF and low peripheral total folate include the following conditions:

 

• Nutritional deficiency of folate
• Antifolate drugs (eg, methotrexate, pemetrexed)
• Proton-coupled folate transporter (PCFT1) deficiency

This article will address the primary causes of cerebral folate deficiency and the disorder resulting from antibodies to the folate receptor. Collectively, these conditions include metabolic recycling defects and disorders of folate transport that typically present with extremely low cerebrospinal fluid concentrations of 5-MTHF below 10 nmol/L prior to treatment.

The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.

If you are a subscriber, please log in.

If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.

If you have never registered before, click Learn More about MedLink Neurology  or view available Service Plans.

Find out how you can join MedLink Neurology